Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

NCT02637687 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02637687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02637687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
Lead sponsor
Bayer
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 16, 2015
Completion date
September 30, 2026
Enrollment
154 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors harboring ntrk fusion